^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
Excerpt:
AZD1775 was administered orally twice per day over 2.5 days per week for up to 2 weeks per 21-day cycle (3 + 3 design)…Confirmed partial responses were observed in two patients carrying BRCA mutations: one with head and neck cancer and one with ovarian cancer....
DOI:
10.1200/JCO.2014.60.4009
